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SUMMARY
Myasthenia gravis is an autoimmune disorder affecting
predominantly women in their reproductive age. The course
of the disease during pregnancy is unpredictable, although
it is more difﬁcult to manage earlier in the gestation.
Myasthenia gravis with antibodies against the muscle-
speciﬁc receptor tyrosine kinase (anti-MuSK) has been
described as a subtype of disease with more localised
clinical features and a poorer response to treatment than
acetylcholine receptor antibody (anti-AChR)-positive
patients. Few cases have been reported in pregnant
women, with deliveries being performed mainly by
caesarean section. We report a successful case of vaginal
delivery and describe our experience providing the ﬁrst
review of the management of this subtype of disease
during pregnancy.
BACKGROUND
Acetylcholine receptor antibody (anti-AChR) anti-
bodies are detected in 75–80% of patients with
generalised myasthenia gravis (MG). Among
patients without anti-AChR antibodies, antimuscle-
speciﬁc receptor tyrosine kinase (anti-MuSK) anti-
bodies are detected in 40% of cases.1
Anti-MuSK-positive MG has a marked female pre-
ponderance. When comparing to anti-AChR-positive
MG the age of onset is in average 10 years later, in
the fourth decade.2–5 Although bulbar symptoms
have been reported to be more common in this
subtype of disease, three phenotypes have recently
been described: oculopharyngeal weakness, with
occasional profound tongue and facial atrophy; neck,
shoulder and respiratory weakness without ocular
weakness; and a phenotype indistinguishable from
anti-AChR-positive MG. Another striking feature of
anti-MuSK-positive MG is the poorer response to
medical treatment, with a lower rate of complete
remission.6–8
Since these antibodies were described for the ﬁrst
time, there have been multiple cases reported in litera-
ture allowing for a better understanding of the clinical
features and appropriate management of these
patients. However, few cases of anti-MuSK-positive
MG during pregnancy have been described. We
report the diagnosis and management of the disease
in a pregnant woman, highlighting the importance of
a multidisciplinary approach of these patients.
CASE PRESENTATION
A 39-year-old patient, gravida 3, para 1, with irrele-
vant medical or familial history, was diagnosed
with generalised immune-mediated MG with ocu-
lobulbar predominance during the ﬁrst trimester of
pregnancy.
The patient referred a 6-month history of bilateral
ptosis, horizontal diplopia and dysphagia. On exam-
ination she presented bilateral ptosis, bilateral limita-
tion of eye abduction, diplopia in all directions of
gaze, dysphonia, facial diparesis, limited cervical
ﬂexion and bilateral superior limb proximal fatigable
weakness. There was no evidence of respiratory com-
promise. Neurophysiological examination with
repetitive nerve stimulation of radial, accessory and
facial nerves was normal. Thoracic CT showed
residual thymic tissue in the anterior mediastinum.
Radioimmunoprecipitation assay revealed negative
anti-AChR antibodies and positive anti-MuSK
antibodies.
After clinical diagnosis of MG the patient initiated
treatment with pyridostigmine (60 mg per os four
times a day) with partial beneﬁt on bulbar weakness.
At 15 and 19 weeks of pregnancy, she presented
two episodes of worsening of myasthenic symptoms,
namely dysphagia, diplopia, cervical weakness
and ptosis, requiring hospitalisation. Intravenous
immunoglobulin (IvIG) 0.4 g/kg body weight per
day, 5 days per month was introduced. The symp-
toms improved but did not resolve. After the second
episode of exacerbation, 125 mg intravenous methyl-
prednisolone was associated during hospitalisation.
Immediately following the corticoid administration,
the patient developed an anaphylactic reaction which
resolved after intravenous treatment with clemastine.
Corticosteroid therapy was suspended and IvIG
administration was increased to 0.4 g/kg body weight
per day, 3 days every 3 weeks. There was no repercus-
sion in the fetal well-being in none of the episodes.
Owing to the patient’s poor response to treatment,
desensitisation therapy was performed at 21 weeks of
pregnancy and methylprednisolone was resumed at a
dosage of 64 mg per os per day. Medication was
maintained until delivery.
Obstetric surveillance was performed according
to the hospital protocol, with normal laboratory
and ultrasound scan routines. Third trimester ultra-
sound scan showed a fetus growing in the 25th
centile, with normal amniotic ﬂuid and no signs of
fetal akinesia.
The patient presented to the emergency room at
34 weeks and 4 days with preterm premature rupture
of membranes (PPROM). On admission amniotic
ﬂuid was clear, Bishop score was 5 and cardiotoco-
graphy was reassuring, demonstrating irregular
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contractility. The patient presented a discrete bilateral ptosis and
facial diparesis. Intravenous ampicillin protocol for PPROM was
initiated. On re-evaluation 5 h 30 min after admission, Bishop
score was 7 and the patient maintained a reassuring cardiotocogra-
phy. Intravenous infusion of oxytocin (5 IU in 500 mL 5% glucose
solution) was initiated to regularise uterine contractility. After dis-
cussion of the case with the neurology team it was decided that,
given the patient’s clinical stability, there was no contraindication
to vaginal delivery. Ambulatory medication was maintained until
delivery. With the beginning of the active phase of labour, intra-
venous hydrocortisone protocol for prophylaxis of adrenal insufﬁ-
ciency was initiated and, after anaesthetic evaluation, epidural
anaesthesia was performed. During labour there was no exacerba-
tion of myasthenic symptoms.
Eutocic delivery was performed uneventfully at 12 h 30 min
after rupture of membranes. A lively male infant (weight:
2360 g; APGAR score 9/10/10) was born, showing no signs of
muscular weakness.
OUTCOME AND FOLLOW-UP
Both the mother and the newborn went from the delivery room
to the puerperium ward. Breastfeeding was initiated in the ﬁrst
hour postpartum, according to the hospital protocol. The
newborn presented no signs of neonatal disease, neither initially
nor in the course of time. The mother showed no immediate
signs of worsening of myasthenic symptoms. Prepartum MG
medication was maintained. Postpartum care was performed
according to the hospital protocol and both the mother and the
newborn were discharged on the second day.
Three months after, the patient presents only with mild facial
diparesis; she is now with prednisolone 20 mg daily per os, in a
reducing dosage schedule, and monthly IvIG (0.4 g/kg body
weight).
DISCUSSION
The management of MG during pregnancy is controversial, and
so is the mode of delivery.
The few cases reported make it impossible to conclude if the
evolution of anti-MuSK-positive MG during pregnancy differs
from that in anti-AChR-positive patients. It is known that the
course of the disease varies widely between women and even
between pregnancies in the same woman.9–12 Exacerbations are
more likely in the ﬁrst trimester and after delivery, though
there are no predictive risk factors to identify mothers at risk
of exacerbation.11 The second and third trimesters are usually
associated with a remission of symptoms due to the normal
immunosuppressive changes occurring during this period.5 6 In
this case, both exacerbations occurred during the second tri-
mester, underlining the importance of a regular evaluation of
these patients, both by a neurologist and an obstetrician. It is
also consensual that the risk of maternal mortality is highest in
the ﬁrst year of disease. Thus, women should delay pregnancy
until the disease is stable.12–15 This patient was diagnosed
during the ﬁrst trimester of pregnancy, when the risk is
highest.
Although MG does not seem to be associated with an
increased risk of spontaneous abortion or preterm labour, Niks
et al16 described their experience with an anti-MuSK-positive
myasthenic pregnant patient who presented two early spontan-
eous abortions and questioned a pathogenic effect of anti-MuSK
antibodies in utero.5 6 14
The physiopathological mechanisms by which anti-MuSK
antibodies cause myasthenic symptoms are not completely
understood.3 8 17 18 Their clariﬁcation may change our under-
standing of labour in these patients. In the few cases reported,
delivery was performed mainly by caesarean section.19–21
However, in light of the knowledge currently available, vaginal
delivery should be the preferred route for birth in all patients
with MG and caesarean section should be performed only for
obstetric indications. Since striated muscle is involved in the
second stage of labour, assisted delivery is frequently indicated
in these patients.5 11 12 15 In this case, given the patient’s clinical
stability and the fact that the third trimester ultrasound showed
a fetus in the 25th centile, we performed an eutocic delivery,
with all the advantages for both mother and infant.
The management of the disease during pregnancy is also contro-
versial. In this case, due to the unknown positivity to anti-MuSK
antibodies by the time of diagnosis, we initiated therapy with acet-
ylcholinesterase inhibitors and titrated the dose according to the
patient’s side effects. The response to treatment was poor, which is
consistent with this subtype of disease.7 22 23 The choice between
plasmapheresis and IvIG during pregnancy is also questionable.
Kanzaki et al20 described their experience with the use of
plasmapheresis in a pregnant woman whose infant developed neo-
natal MG. Although both plasmapheresis and IvIG seem to be
effective in the treatment of myasthenic exacerbations in
anti-MuSK-positive MG, plasmapheresis seems to be associated
with an increased risk for prematurity. Moreover, due to the
physiological changes of coagulation factors that occur during
pregnancy, plasmapheresis should be considered a second choice
in the treatment of these patients.5 7 12 24
Most patients improve their symptoms with steroids or other
immunosuppressive drugs.2 4 7 In this case, oral methylpredni-
solone was initiated after desensitisation due to the persistence
of symptoms despite regular therapy with IvIG. With this asso-
ciation, clinical stability was achieved during pregnancy, labour
and puerperium. However, it should be noted that the use of
methylprednisolone is associated with an increased risk of
palate cleft when used in the ﬁrst trimester and that high doses
have been associated with an increased risk of premature
rupture of membranes (PRM), as stated in the case above.12 25
Irrespective of the treatment with corticosteroids, pregnant
patients with MG have a three times higher risk of PRM. It
has been suggested that this complication might be a conse-
quence of polyhydramnios associated with neonatal MG.5 11
Since in this case the infant showed no prenatal or postnatal
signs of disease, we cannot exclude the relation between PRM
and the use of corticosteroids during the second and third
trimesters.
Other immunosuppressive agents were not considered due to
their reported unsafety during pregnancy.5 12 14 26 Although
azathioprine has been considered safe, an increased risk of gesta-
tional complications such as prematurity, fetal growth restric-
tion, low birth weight and increased risk of fetal
myelosuppression have been described.24 26 Given the patient’s
moderate symptoms, we decided not to introduce this agent
during pregnancy.
The role of thymectomy in non-thymomatous patients is
unclear and it seems to be of little value in anti-MuSK-positive
patients.6 7 22 Besides, when considered in pregnant patients, it
should be performed after a stable postpartum period due to
the delayed therapeutic effect and surgical risks.12 Therefore, it
was not considered in this case.
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Learning points
▸ The effect of antimuscle-speciﬁc receptor tyrosine kinase
(anti-MuSK) antibodies on the mechanism of labour is yet to
be clariﬁed.
▸ Positivity to anti-MuSK antibodies poses an extra challenge
in the management of myasthenic patients due to their
poorer response to the classical therapeutic approaches.
▸ Eutocic delivery should be the ﬁrst option in clinically stable
pregnant women with myasthenia gravis and caesarean
section should be performed only for obstetric indications.
▸ Since the course of disease during pregnancy is
unpredictable, a multidisciplinary approach is essential in the
management of these patients.
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